Skip to main content

Adynxx, Inc. (ADYX)

OTCMKTS: ADYX · IEX Real-Time Price · USD
0.0150 -0.0050 (-25.00%)
Oct 25, 2021 1:37 PM EDT - Market closed
Market Cap87,118
Revenue (ttm)589,000
Net Income (ttm)-8.73M
Shares Out5.81M
EPS (ttm)-1.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume200
Open0.0150
Previous Close0.0200
Day's Range0.0150 - 0.0150
52-Week Range0.0200 - 1.1800
Beta2.99
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About ADYX

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

IndustryBiotechnology
Founded2007
CEODavid Johnson
Employees6
Stock ExchangeOTCMKTS
Ticker SymbolADYX
Full Company Profile

Financial Performance

In 2018, Adynxx's revenue was $2.22 million, an increase of 9.76% compared to the previous year's $2.02 million. Losses were -$8.42 million, -67.26% less than in 2017.

Financial Statements

News

There is no news available yet.